Skip to main content
37596 search results for:

315 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-11-2023 | Acute Lymphoblastic Leukemia | OriginalPaper

    Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome–positive acute lymphoblastic leukemia: two-case report

    ABL tyrosine kinase inhibitors (TKIs) act an irreplaceable role in the management of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). The treatment of these diseases has been revolutionized by the application of …

  2. Open Access 14-09-2023 | Gout | ReviewPaper

    Patient characteristics, surgical treatment, and outcomes in spinal gout: a systematic review of 315 cases

    Gout is a common metabolic disorder affecting the joint and soft tissues, as a result of increased uric acid causing depositions of monosodium urate crystals [ 1 ]. In patients with gout, long term tophus formation and joint flares may progress to …

  3. Open Access 01-12-2023 | Diabetic Foot | OriginalPaper

    Circ_072697 knockdown promotes advanced glycation end products-induced cell proliferation and migration in HaCaT cells via miR-3150a-3p/KDM2A axis

    Diabetic foot ulcer (DFU) is a prevalent complication of diabetes, which is an important factor leading to disability and death of diabetes patients. It is reported that 19–34% of diabetes may be affected by DFU in their lifetime [ 1 ]. Patients …

  4. 01-11-2023 | Imatinib | OriginalPaper

    Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the AblT315I mutant kinase to combat imatinib resistance in chronic myeloid leukemia

    The discovery of imatinib, a specific inhibitor of Abl kinase, revolutionized the therapeutic approach to chronic myeloid leukemia (CML); however, its efficacy can be impeded by the emergence of novel mutations within the kinase domain …

  5. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

    Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” …

  6. 06-05-2022 | Acute Lymphoblastic Leukemia | OriginalPaper

    Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system

    Imatinib and second-generation tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, overcoming TKI resistance due to the T315I gatekeeper …

  7. Open Access 01-10-2021 | Macroalbuminuria | OriginalPaper

    Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

    Approximately 40% of patients with type 2 diabetes develop diabetic kidney disease (DKD) [ 1 ], a progressive condition that represents the leading cause of end-stage kidney disease (ESKD) [ 1 ]. Furthermore, DKD has been shown to be associated …

  8. Open Access 01-04-2021 | Denture | OriginalPaper

    Biological and technical complications in root cap–retained overdentures after 3–15 years in situ: a retrospective clinical study

    Due to the continuous development of oral care and strategies and preventative measures, the frequency of caries and periodontitis has decreased over the past several decades. Consequently, the number of people suffering from total edentulism is …

  9. 01-02-2021 | Alopecia | OriginalPaper

    A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia

    Chemotherapy-induced alopecia (CIA), a non-cicatricial alopecia, is a common dermatologic adverse event (AE) associated with cytotoxic chemotherapeutic agent use in cancer patients [ 1 , 2 ]. Many chemotherapies have shown to induce alopecia such …

  10. Open Access 01-12-2023 | Chronic Myeloid Leukemia | Erratum

    Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

  11. Open Access 01-12-2019 | Breast Cancer | OriginalPaper

    Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

    Breast cancer remains one of the four major cancers, and is expected to account for approximately 30% of all new cancer diagnoses in women in the USA, making it the leading cause of cancer-related deaths in women aged 20–59 years [ 1 ].

  12. Open Access 01-12-2022 | Chronic Myeloid Leukemia | OriginalPaper

    Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

    Introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML) [ 1 – 3 ], but resistance to TKIs remains a challenge. The BCR-ABL1 T315I “gatekeeper” (the most common kinase domain) mutation …

  13. Open Access 01-12-2022 | Chronic Myeloid Leukemia | Erratum

    Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

    The original article [ 1 ] contained three erroneous citations and other minor typesetting errors in the text which have since been amended.

  14. Open Access 01-12-2022 | Chronic Myeloid Leukemia | OriginalPaper

    Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation

    Chronic myeloid leukemia (CML) is a myeloproliferative disorder involving the hematopoietic stem cell compartment that is hallmarked by a typical reciprocal translocation between chromosomes 9 and 22. The formed bcr-abl fusion gene is translated …

  15. Open Access 01-12-2019 | OriginalPaper

    Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report

    Desmoid tumors (DTs) or aggressive fibromatoses are rare, with a yearly incidence of 2–5 per 1 million population. Not apt to metastasize, they represent locally infiltrating soft tissue tumors that may occur anywhere in the body [ 1 ]. A seemingly …

  16. 01-04-2020 | Acute Lymphoblastic Leukemia | OriginalPaper

    T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes

    A single-center retrospective was performed with consecutive de novo BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients who received TKI-containing therapy between January 2010 and December 2018 to review the incidence, treatment, and …

  17. 01-07-2019 | Chronic Myeloid Leukemia | OriginalPaper

    Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation

    A 42-year-old female complaining of fever and night sweats was diagnosed with acute megakaryoblastic blast phase chronic myeloid leukemia (CML-BP). She had massive splenomegaly, left pleural effusion with leukemia infiltration, and moderate …

  18. Open Access 01-12-2021 | Imatinib | Erratum

    Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

    An amendment to this paper has been published and can be accessed via the original article.

  19. 01-07-2019 | Flush | News

    Interferon alpha/LTX-315

    Various toxicities
  20. Open Access 17-01-2024 | Online First

    Glycogen Synthase Kinase-3β Inhibitor VP3.15 Ameliorates Neurogenesis, Neuronal Loss and Cognitive Impairment in a Model of Germinal Matrix-intraventricular Hemorrhage of the Preterm Newborn

    Advances in neonatology have significantly reduced mortality rates due to prematurity. However, complications of prematurity have barely changed in recent decades. Germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most severe …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.